Henrik Moebitz
Novartis
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Henrik Moebitz.
Bioorganic & Medicinal Chemistry Letters | 2008
Achim Schlapbach; Roland Feifel; Stuart Hawtin; Richard Heng; Guido Koch; Henrik Moebitz; Laszlo Revesz; Clemens Scheufler; Juraj Velcicky; Rudolf Waelchli; Christine Huppertz
Pyrrolo-pyrimidones of the general structure 1 were synthesized and evaluated for their potential as MK2 inhibitors. Potent derivatives were discovered which inhibit MK2 in the nanomolar range and show potent inhibition of cytokine release from LPS-stimulated monocytes. These derivatives were shown to inhibit phosphorylation of hsp27, a downstream target of MK2 and are modestly selective in a panel of 28 kinases.
Bioorganic & Medicinal Chemistry Letters | 2010
Juraj Velcicky; Roland Feifel; Stuart Hawtin; Richard Heng; Christine Huppertz; Guido Koch; Markus Kroemer; Henrik Moebitz; Laszlo Revesz; Clemens Scheufler; Achim Schlapbach
New, selective 3-aminopyrazole based MK2-inhibitors were discovered by scaffold hopping strategy. The new derivatives proved to inhibit intracellular phosphorylation of hsp27 as well as LPS-induced TNFalpha release in cells. In addition, selected derivative 14e also inhibited LPS-induced TNFalpha release in vivo.
Cancer Discovery | 2018
Yijun Gao; Matthew T. Chang; Daniel McKay; Na Na; Bing Zhou; Rona Yaeger; Neilawattie M. Torres; Keven Muniz; Matthias Drosten; Mariano Barbacid; Giordano Caponigro; Darrin Stuart; Henrik Moebitz; David B. Solit; Omar Abdel-Wahab; Barry S. Taylor; Zhan Yao; Neal Rosen
Mutations at multiple sites in MEK1 occur in cancer, suggesting that their mechanisms of activation might be different. We analyzed 17 tumor-associated MEK1 mutants and found that they drove ERK signaling autonomously or in a RAS/RAF-dependent manner. The latter are sensitive to feedback inhibition of RAF, which limits their functional output, and often cooccur with RAS or RAF mutations. They act as amplifiers of RAF signaling. In contrast, another class of mutants deletes a hitherto unrecognized negative regulatory segment of MEK1, is RAF- and phosphorylation-independent, is unaffected by feedback inhibition of upstream signaling, and drives high ERK output and transformation in the absence of RAF activity. Moreover, these RAF-independent mutants are insensitive to allosteric MEK inhibitors, which preferentially bind to the inactivated form of MEK1. All the mutants are sensitive to an ATP-competitive MEK inhibitor. Thus, our study comprises a novel therapeutic strategy for tumors driven by RAF-independent MEK1 mutants.Significance: Mutants with which MEK1 mutants coexist and their sensitivity to inhibitors are determined by allele-specific properties. This study shows the importance of functional characterization of mutant alleles in single oncogenes and identifies a new class of MEK1 mutants, insensitive to current MEK1 inhibitors but treatable with a new ATP-competitive inhibitor. Cancer Discov; 8(5); 648-61. ©2018 AACR.See related commentary by Maust et al., p. 534This article is highlighted in the In This Issue feature, p. 517.
Biochimica et Biophysica Acta | 2015
Eric J. Martin; Stefan Knapp; Richard A. Engh; Henrik Moebitz; Thibault Varin; Benoît Roux; Jens Meiler; Valerio Berdini; Alexander Baumann; Michal Vieth
Recent advances in understanding the activity and selectivity of kinase inhibitors and their relationships to protein structure are presented. Conformational selection in kinases is studied from empirical, data-driven and simulation approaches. Ligand binding and its affinity are, in many cases, determined by the predetermined active and inactive conformation of kinases. Binding affinity and selectivity predictions highlight the current state of the art and advances in computational chemistry as it applies to kinase inhibitor discovery. Kinome wide inhibitor profiling and cell panel profiling lead to a better understanding of selectivity and allow for target validation and patient tailoring hypotheses. This article is part of a Special Issue entitled: Inhibitors of Protein Kinases.
Bioorganic & Medicinal Chemistry Letters | 2011
Julien Chapelat; Frederic Berst; Andreas Marzinzik; Henrik Moebitz; Peter Drueckes; Doriano Fabbro; Joerg Trappe; Dieter Seebach
Protein kinases are widely recognized as important therapeutic targets due to their involvement in signal transduction pathways. These pathways are tightly controlled and regulated, notably by the ability of kinases to selectively phosphorylate a defined set of substrates. As part of a study on the substrate requirements of Insulin-like Growth Factor 1 Receptor (IGF-1R) and Insulin Receptor (InsR), we evaluated and applied a universal assay system able to monitor the phosphorylation of unlabelled peptides of any length in real time. In contrast to already reported profiling methodologies, we were able to assess the k(cat)/K(M) ratio of peptides as short as tetramers. Notably, we were able to identify an efficient pentamer substrate that exhibited kinetic properties close to those of a 250-amino acid protein derived from IRS-1, a natural substrate of IGF-1R and InsR.
British Journal of Pharmacology | 2015
Doriano Fabbro; Sandra W. Cowan-Jacob; Henrik Moebitz
Archive | 2010
Sangamesh Badiger; Murali Chebrolu; Mathias Frederiksen; Philipp Holzer; Konstanze Hurth; Rainer Martin Lueoend; Rainer Machauer; Henrik Moebitz; Ulf Neumann; Rita Ramos; Heinrich Rueeger; Marina Tintelnot-Blomley; Siem Jacob Veenstra; Markus Voegtle
Archive | 2012
Mark G. Bock; Christoph Gaul; Venkateshwar Rao Gummadi; Henrik Moebitz; Saumitra Sengupta
European Journal of Medicinal Chemistry | 2012
Julien Chapelat; Frederic Berst; Andreas Marzinzik; Henrik Moebitz; Peter Drueckes; Joerg Trappe; Doriano Fabbro; Dieter Seebach
Archive | 2015
Zhenxing Du; Samuel Hintermann; Konstanze Hurth; Sébastien Jacquier; Hansjoerg Lehmann; Henrik Moebitz; Nicolas Soldermann; Aleksandar Stojanovic